Harry H. Yoon, MD
Disclosures: Grant or research support-Merck and Company, Inc.-|Grant or research support-Bristol-Myers Squibb-|Membership on advisory committees or review panels, board membership, etc.-ALX Oncology-|Membership on advisory committees or review panels, board membership, etc.-Oncxerna-|Membership on advisory committees or review panels, board membership, etc.-Zymeworks-|Membership on advisory committees or review panels, board membership, etc.-Astellas-|Membership on advisory committees or review panels, board membership, etc.-BeiGene-|Membership on advisory committees or review panels, board membership, etc.-Merck and Company, Inc.-|Membership on advisory committees or review panels, board membership, etc.-Bristol-Myers Squibb-|Membership on advisory committees or review panels, board membership, etc.-Macrogenics-|honoraria for education symposium-BeiGene-|Membership on advisory committees or review panels, board membership, etc.-AstraZeneca- - 05/10/2021
HARRY YOON, M

HARRY H. YOON, M.D., M.H.S

 

 

 

Current Title:  Chair, Gastroesophageal Cancer Disease Group, Mayo Clinic Comprehensive Cancer Center; Consultant, Department of Oncology, Mayo Clinic; Associate Professor of Oncology, Mayo Clinic College of Medicine.

 

Education:  Yale School of Medicine (M.D.); Johns Hopkins Schools of Medicine and Public Health (Master of Health Science, M.H.S.); Yale College (B.S., Molecular Biophysics and Biochemistry)

 

Dr. Yoon is a GI oncologist at the Mayo Clinic, where he leads an R01-funded clinical/translational research program to understand how PD-1 blockade modulates the gastric tumor microenvironment.  He is a frequent speaker at internationally attended scientific conferences, and serves on the guidelines panel of the National Comprehensive Cancer Network (NCCN) for Gastric/Esophageal Cancer and on steering committees of global registrational trials.

 

Page 1 of 26

July 11, 2022